Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, Neuland Laboratories has informed that it enclosed the schedule of Q2 FY 2026 Earnings Call details.
The above information is a part of company’s filings submitted to BSE.